26th Annual Key Topics in GI – IBD in 2023 and Beyond

Registration

$187.50 for practicing physicians. All other professions register at no cost.
You must be a paid registrant to claim continuing education credits for this event.

This event will also be available virtual, upon registration please note how you prefer to attend.

Attendees must register for an account, add a ticket to their event cart, and complete the check out transaction in order to register. Scroll down to add a ticket to your event cart. 

Learning Objectives

Thursday PM
• To understand what factors are risk factors for development of Crohns disease and what factors are predictors of     disease progression
• To understand the role of serotonin and interferon lambda in immune regulation of IBD
• To understand which dietary factors impact on IBD outcomes

Friday
• To understand the impact of COVID-19 pandemic on persons with IBD
• To understand how patients with IBD responded to COVID-19 vaccinations and infections
• To learn what vaccines are indicated and the optimal timing for their administration in persons with IBD
• To learn approaches to optimize IBD management during pregnancy
• To consider what the optimal endpoints of mucosal healing in IBD should be
• To understand aspects of nutrition management in IBD
• To learn the outcomes from switching biological originator therapy to biosimilar therapy
• To develop an approach to therapeutic decision making in Cohn’s disease
• To develop an approach to therapeutic decision making in ulcerative colitis
• To learn whether combining advanced therapies in IBD is safe and effective

Agenda

Thursday June 15 PM

1230 Welcome – Charles Bernstein
Moderator: Jean Eric Ghia
1235-1305 Predictors of development of Crohn’s disease – Dr Ken Croitoru, University of Toronto
1305-1335 Biomarkers that predict Crohn’s disease outcomes – Dr Mark Silverberg, University of Toronto
1335-1405 Emerging roles of gut serotonin in regulation of immune response, microbiota composition and colitis – Dr Waliul Khan  McMaster University
1406-1436 IFN lambda a new regulator in colonic inflammation? – Deanna Santer University of Manitoba

Break: 1440-1500

1500-1530 Insights into inflammatory bowel disease and effects of dietary fat using preclinical models – Dr. Kevan Jacobson University of British Columbia
1531-1601 Dietary fibre subtypes in IBD –  Dr. Heather Armstrong—University of Manitoba
1601-1645 Panel discussion: All speakers
Dr Jean Eric Ghia

Friday June 16

0825-830 Welcome – Dr Charles Bernstein
Moderator: Don Duerksen, University of Manitoba
0830-900 2023 IBD Impact Report in Canada- Gilaad Kaplan U Calgary
0900-930 How did COVID-19 affect mental health and access to care in persons with IBD-Seth Shaffer U Manitoba
0930-1000  Vaccinations and IBD; What do patients need and are they getting it?- Millie Long UNC
1000-1030  Optimizing management of IBD patients in pregnancy –Yvette Leung UBC

1030-1050 Break

Moderator: Don Duerksen, University of Manitoba
1050-1120 Endoscopy, Histology or both as a target in IBD – Fernando Magro University of Porto, Portugal
1120-1150 Nutrition as treatment in IBD-evidence and clinical practice –Iris Dotan  Rabin Medical Centre, Petah Tikva, Israel
1150-1230 Don Duerksen University of Manitoba Panel Discussion

1230-1330-Lunch

Afternoon moderator – Seth Shaffer, University of Manitoba
1330-1400 Choosing therapy in CD – Bincy Abraham,  Houston Methodist Hospital/Weill Cornell Medical College
1400-1430 Choosing therapy in UC – Hillary Steinhart, University of Toronto
1430-1500 Biosimilars 2 years post mandatory nonmedical switch – Greg Rosenfeld, UBC
1500-1530 Combined biological therapies in IBD: future, fact or fiction?” Peter Lakatos, McGill University,”

1530-1550 Break

1550-1700 Panel discussion – Dr Charles Bernstein

Contact

Rem Binua –  rbinua@hsc.mb.ca
204-789-3628 (phone)

Hotel

Preferred rate is available The Fort Garry Hotel Spa and Conference Centre